CS
ALXO icon

Credit Suisse’s ALX Oncology ALXO Stock Holding History

Credit Suisse’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$176K Buy
+15,765
New +$221K ﹤0.01% 2907
2023
Q2 		– Sell
-21,297
Closed -$96.3K – 3165
2023
Q1 		$96.3K Buy
21,297
+4
+0% +$30 ﹤0.01% 3209
2022
Q4 		$240K Sell
21,293
-4,940
-19% -$55.5K ﹤0.01% 3122
2022
Q3 		$250K Buy
26,233
+11,076
+73% +$129K ﹤0.01% 3157
2022
Q2 		$121K Buy
15,157
+940
+7% +$10.2K ﹤0.01% 3498
2022
Q1 		$240K Buy
14,217
+383
+3% +$6.54K ﹤0.01% 3322
2021
Q4 		$297K Buy
13,834
+9,456
+216% +$408K ﹤0.01% 4115
2021
Q3 		$324K Buy
4,378
+271
+7% +$18.1K ﹤0.01% 4054
2021
Q2 		$224K Sell
4,107
-2,026
-33% -$121K ﹤0.01% 4241
2021
Q1 		$452K Sell
6,133
-7,411
-55% -$583K ﹤0.01% 3837
2020
Q4 		$1.17M Buy
+13,544
New +$815K ﹤0.01% 3233

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Credit Suisse's ALXO Position: Q1 2024 in Review

Credit Suisse opened a new position in ALX Oncology (ALXO) in Q1 2024: 15,765 shares worth $176K. The stake represents ﹤0.01% of the portfolio and ranks #2907 among its holdings. This is a return to the name: Credit Suisse previously reported a position in ALXO as recently as Q1 2023.

Credit Suisse first reported a position in ALXO in Q4 2020 and has held it in 11 quarters since. The position peaked at $1.17M in Q4 2020. 106 funds tracked by Wall St. Rank hold ALXO as of Q1 2024.

  • Credit Suisse held 15,765 shares of ALX Oncology worth $176K as of Q1 2024.
  • ALX Oncology was a new Credit Suisse position in Q1 2024.
  • ALX Oncology made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2907 holding.
  • Credit Suisse first reported a position in ALX Oncology in Q4 2020 and has held it in 11 quarters since.
  • Credit Suisse's ALX Oncology position peaked at $1.17M in Q4 2020.
  • 106 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.